413 related articles for article (PubMed ID: 32367193)
1. Dysregulated signalling pathways in innate immune cells with cystic fibrosis mutations.
Lara-Reyna S; Holbrook J; Jarosz-Griffiths HH; Peckham D; McDermott MF
Cell Mol Life Sci; 2020 Nov; 77(22):4485-4503. PubMed ID: 32367193
[TBL] [Abstract][Full Text] [Related]
2. Current concepts of immune dysregulation in cystic fibrosis.
Rieber N; Hector A; Carevic M; Hartl D
Int J Biochem Cell Biol; 2014 Jul; 52():108-12. PubMed ID: 24495876
[TBL] [Abstract][Full Text] [Related]
3. Cystic fibrosis and the innate immune system: therapeutic implications.
Conese M
Endocr Metab Immune Disord Drug Targets; 2011 Mar; 11(1):8-22. PubMed ID: 21348822
[TBL] [Abstract][Full Text] [Related]
4. TLR-4-mediated innate immunity is reduced in cystic fibrosis airway cells.
John G; Yildirim AO; Rubin BK; Gruenert DC; Henke MO
Am J Respir Cell Mol Biol; 2010 Apr; 42(4):424-31. PubMed ID: 19502387
[TBL] [Abstract][Full Text] [Related]
5. Phagocytic and signaling innate immune receptors: are they dysregulated in cystic fibrosis in the fight against Pseudomonas aeruginosa?
Sallenave JM
Int J Biochem Cell Biol; 2014 Jul; 52():103-7. PubMed ID: 24508137
[TBL] [Abstract][Full Text] [Related]
6. Dysregulated Calcium Homeostasis in Cystic Fibrosis Neutrophils Leads to Deficient Antimicrobial Responses.
Robledo-Avila FH; Ruiz-Rosado JD; Brockman KL; Kopp BT; Amer AO; McCoy K; Bakaletz LO; Partida-Sanchez S
J Immunol; 2018 Oct; 201(7):2016-2027. PubMed ID: 30120123
[TBL] [Abstract][Full Text] [Related]
7. Optimal complement-mediated phagocytosis of Pseudomonas aeruginosa by monocytes is cystic fibrosis transmembrane conductance regulator-dependent.
Van de Weert-van Leeuwen PB; Van Meegen MA; Speirs JJ; Pals DJ; Rooijakkers SH; Van der Ent CK; Terheggen-Lagro SW; Arets HG; Beekman JM
Am J Respir Cell Mol Biol; 2013 Sep; 49(3):463-70. PubMed ID: 23617438
[TBL] [Abstract][Full Text] [Related]
8. Innate immune response in CF airway epithelia: hyperinflammatory?
Machen TE
Am J Physiol Cell Physiol; 2006 Aug; 291(2):C218-30. PubMed ID: 16825601
[TBL] [Abstract][Full Text] [Related]
9. Impact of
Meoli A; Eickmeier O; Pisi G; Fainardi V; Zielen S; Esposito S
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293274
[TBL] [Abstract][Full Text] [Related]
10. The NF-kappaB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential.
Bodas M; Vij N
Discov Med; 2010 Apr; 9(47):346-56. PubMed ID: 20423679
[TBL] [Abstract][Full Text] [Related]
11. An activated immune and inflammatory response targets the pancreas of newborn pigs with cystic fibrosis.
Abu-El-Haija M; Sinkora M; Meyerholz DK; Welsh MJ; McCray PB; Butler J; Uc A
Pancreatology; 2011; 11(5):506-15. PubMed ID: 22057257
[TBL] [Abstract][Full Text] [Related]
12. Relationships among CFTR expression, HCO3- secretion, and host defense may inform gene- and cell-based cystic fibrosis therapies.
Shah VS; Ernst S; Tang XX; Karp PH; Parker CP; Ostedgaard LS; Welsh MJ
Proc Natl Acad Sci U S A; 2016 May; 113(19):5382-7. PubMed ID: 27114540
[TBL] [Abstract][Full Text] [Related]
13. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
[TBL] [Abstract][Full Text] [Related]
14. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
[TBL] [Abstract][Full Text] [Related]
15. Absence of the cystic fibrosis transmembrane regulator (Cftr) from myeloid-derived cells slows resolution of inflammation and infection.
Bonfield TL; Hodges CA; Cotton CU; Drumm ML
J Leukoc Biol; 2012 Nov; 92(5):1111-22. PubMed ID: 22859830
[TBL] [Abstract][Full Text] [Related]
16. Genotype and phenotype in cystic fibrosis.
Zielenski J
Respiration; 2000; 67(2):117-33. PubMed ID: 10773783
[TBL] [Abstract][Full Text] [Related]
17. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.
Aslam AA; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2023 Mar; 3(3):CD012040. PubMed ID: 36866921
[TBL] [Abstract][Full Text] [Related]
18. CFTR-mediated monocyte/macrophage dysfunction revealed by cystic fibrosis proband-parent comparisons.
Zhang X; Moore CM; Harmacek LD; Domenico J; Rangaraj VR; Ideozu JE; Knapp JR; Woods KJ; Jump S; Jia S; Prokop JW; Bowler R; Hessner MJ; Gelfand EW; Levy H
JCI Insight; 2022 Mar; 7(6):. PubMed ID: 35315363
[TBL] [Abstract][Full Text] [Related]
19. Distribution of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations in a Cohort of Patients Residing in Palestine.
Siryani I; Jama M; Rumman N; Marzouqa H; Kannan M; Lyon E; Hindiyeh M
PLoS One; 2015; 10(7):e0133890. PubMed ID: 26208274
[TBL] [Abstract][Full Text] [Related]
20. Emerging Concepts in Defective Macrophage Phagocytosis in Cystic Fibrosis.
Jaganathan D; Bruscia EM; Kopp BT
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
